论文部分内容阅读
目的:了解长期服用氯氮平的慢性精神分裂症患者伴发代谢综合征(MS)的发生率及相关因素。方法:对370例长期服用氯氮平治疗的慢性住院精神分裂症患者测量身高、体质量、腰围和血压,空腹血糖、血总胆固醇、三酰甘油、高密度脂蛋白胆固醇及进行氯氮平血药浓度测定。结果:长期服用氯氮平治疗的慢性住院精神分裂症患者高血糖、高血压、肥胖、血脂异常及MS的发生率分别为33.2%、24.3%、42.4%、54.9%及19.5%,结论:长期服用氯氮平治疗的慢性住院精神分裂症患者伴发代谢综合征的发生率较高。
Objective: To understand the incidence and related factors of metabolic syndrome (MS) in patients with chronic schizophrenia who are taking clozapine for a long time. Methods: 370 patients with chronic in-hospital schizophrenia treated with clozapine were measured for height, body mass, waist circumference and blood pressure, fasting blood glucose, total cholesterol, triglyceride, high density lipoprotein cholesterol, and clozapine Drug concentration determination. Results: The incidences of hyperglycemia, hypertension, obesity, dyslipidemia and MS in patients with chronic schizophrenia treated with long-term clozapine were 33.2%, 24.3%, 42.4%, 54.9% and 19.5%, respectively. Conclusion: Chronic schizophrenic patients treated with clozapine have a higher incidence of metabolic syndrome.